Zura Bio holds an exclusive license for the development and commercialization of Torudokimab
IL33 is a validated drug target in both chronic obstructive pulmonary disease (COPD) and asthma.
Drug well tolerated in Phase 1 and 2 trials conducted by Lilly and shows utility in diseases driven by epithelial inflammation.
Targeting IL33 In Epithelial Driven Diseases
IL33 is a member of the IL1 cytokine family that is constitutively expressed in structural and lining cells including fibroblasts, endothelial, and epithelial cells of skin, gastrointestinal tract, and lungs
IL33 is released from the epithelium by disease exacerbating environmental factors and is an important amplifier of innate inflammation during exacerbations
Polymorphisms in IL33 and ST2 are associated with increased eosinophil production as well as respiratory diseases such as COPD and Severe Asthma.
IL33 inhibition clinically validated in Severe asthma, COPD, and subsets of other epithelial disorders
IL33: Roles in Allergic Inflammation and Therapeutic Perspectives
Chan BCL, Lam CWK, Tam L-S and Wong CK (2019) Front. Immunol. 10:364.
Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation
Cohen, E., Scott, I., Majithiya, J. et al. Nat Commun 6, 8327 (2015).
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma
Wechsler ME, Ruddy MK, Pavord ID, Israel E, Rabe KF, Ford LB, Maspero JF, Abdulai RM, Hu CC, Martincova R, Jessel A, Nivens MC, Amin N, Weinreich DM, Yancopoulos GD, Goulaouic H. N Engl J Med. 2021 Oct 28;385(18):1656-1668.